These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25495098)

  • 1. Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study.
    Wang Y; Chen J; Wu S; Hu C; Li X; Wang Y; Yang Y; Rajan N; Chen Y; Chen Y; Luo Z; Chen W
    BMC Cancer; 2014 Dec; 14():940. PubMed ID: 25495098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study.
    Chen J; Wu S; Hu C; Yang Y; Rajan N; Chen Y; Yang C; Li J; Chen W
    Clinicoecon Outcomes Res; 2016; 8():97-111. PubMed ID: 27217784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study.
    Hu C; Wang Y; Chen J; Wu S; Li X; Wang Y; Yang Y; Rajan N; Papadimitropoulos M; Xiao Q; Zhan H; Chen W
    Thorac Cancer; 2014 Sep; 5(5):365-76. PubMed ID: 26767027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy analysis of third-generation plus platinum doublets in the first-line chemotherapy of advanced non-small cell lung cancer].
    Zhao LD; Zhang XR; Li JL; Wang ZP; Wang Y; Hao XZ; Hu XS; Zhou SY; Sun Y; Shi YK
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(22):1527-31. PubMed ID: 22944054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
    Zhai X; Zheng Q; Yang L; Zhu Y; Li J; Liu Y; Wang Z
    Sci Rep; 2017 May; 7(1):1453. PubMed ID: 28469143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
    Li X; Wang Y; Wang Y; Chen J; Wu S; Hu C; Yang Y; Rajan N; Papadimitropoulos M; Chen Y; Peng T; Chen W
    Drugs Real World Outcomes; 2015 Mar; 2(1):87-97. PubMed ID: 27747618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum rechallenge in patients with advanced NSCLC: a pooled analysis.
    Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Ardine M; Barni S
    Lung Cancer; 2013 Sep; 81(3):337-342. PubMed ID: 23891507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
    Treat J; Scagliotti GV; Peng G; Monberg MJ; Obasaju CK; Socinski MA
    Lung Cancer; 2012 May; 76(2):222-7. PubMed ID: 22115704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
    Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
    Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
    Xu H; Xu F; Zhu W; Ying J; Wang Y
    Thorac Cancer; 2018 Aug; 9(8):1005-1011. PubMed ID: 29917332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.